General Catalyst Group Management, LLC
13F Reported Value
ⓘ$188.5M
Holdings
14
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
General Catalyst Group Management, LLC disclosed 14 positions worth $188.5M in its Form 13F-HR for Q2 2026, led by $AVBP (ArriVent BioPharma, Inc.) at 27.6% of the equity portfolio, followed by $PBLS and $CART. During the quarter the fund opened 4 new positions and exited 2 — including a new stake in $PBLS and a full exit from $IOT. The portfolio is most concentrated in Healthcare (79.4% of disclosed assets). All figures are sourced directly from General Catalyst Group Management, LLC’s Form 13F-HR filing with the SEC under CIK 1637946.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$51.9M1,494,786 sh - —
Quality
$43.8M1,600,937 sh - 70.6#214
Quality
$33.7M710,711 sh - 10.3
Quality
$30.9M1,035,910 sh - —
Quality
$15.2M810,272 sh - —
Quality
$4.0M305,233 sh - 10.0
Quality
$3.9M4,884,186 sh - 21.7
Quality
$1.3M74,179 sh - 50.6
Quality
$949.7K54,677 sh - 68.7
Quality
$925.2K3,882 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ArriVent BioPharma, Inc.$AVBP | — | $51.9M | 1,494,786 |
 Parabilis Medicines, Inc.$PBLS | — | $43.8M | 1,600,937 |
 Maplebear Inc.$CART | 70.6#214 | $33.7M | 710,711 |
 Maze Therapeutics, Inc.$MAZE | 10.3 | $30.9M | 1,035,910 |
 Odyssey Therapeutics, Inc.$ODTX | — | $15.2M | 810,272 |
 Eikon Therapeutics, Inc.$EIKN | — | $4.0M | 305,233 |
 FRACTYL HEALTH, INC.$GUTS | 10.0 | $3.9M | 4,884,186 |
 Ethos Technologies Inc.$LIFE | 21.7 | $1.3M | 74,179 |
 Coupang, Inc.$CPNG | 50.6 | $949.7K | 54,677 |
 AMAZON COM INC$AMZN | 68.7 | $925.2K | 3,882 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of General Catalyst Group Management, LLC's 14 positions.
Showing top 10 of 14 holdings.
Sector Allocation
Healthcare
$149.7M
Industrials
$34.2M
Consumer Discretionary
$2.3M
Financials
$1.3M
Technology
$1.0M
Full Holdings — General Catalyst Group Management, LLC (Q2 2026)
All 14 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AVBP | ArriVent BioPharma, Inc. | $51.9M | 27.6% | +0% | — |
| 2 | $PBLS | Parabilis Medicines, Inc. | $43.8M | 23.2% | NEW | — |
| 3 | $CART | Maplebear Inc. | $33.7M | 17.9% | +0% | 70.6 |
| 4 | $MAZE | Maze Therapeutics, Inc. | $30.9M | 16.4% | +0% | 10.3 |
| 5 | $ODTX | Odyssey Therapeutics, Inc. | $15.2M | 8.0% | NEW | — |
| 6 | $EIKN | Eikon Therapeutics, Inc. | $4.0M | 2.1% | +0% | — |
| 7 | $GUTS | FRACTYL HEALTH, INC. | $3.9M | 2.1% | -0% | 10 |
| 8 | $LIFE | Ethos Technologies Inc. | $1.3M | 0.7% | +0% | 21.7 |
| 9 | $CPNG | Coupang, Inc. | $949,739 | 0.5% | +49% | 50.6 |
| 10 | $AMZN | AMAZON COM INC | $925,236 | 0.5% | +50% | 68.7 |
| 11 |  $META | Meta Platforms, Inc. | $743,543 | 0.4% | +101% | 79.6 |
| 12 |  $DASH | DoorDash, Inc. | $525,911 | 0.3% | NEW | 71 |
| 13 |  $CVNA | CARVANA CO. | $425,526 | 0.2% | NEW | 71.6 |
| 14 |  $FIG | Figma, Inc. | $268,546 | 0.1% | +0% | 43.9 |
New Positions (4)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for General Catalyst Group Management, LLC including:
Track General Catalyst Group Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for General Catalyst Group Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: General Catalyst Group Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For General Catalyst Group Management, LLC (SEC CIK: 1637946), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in General Catalyst Group Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.